News

Transfusion doesn’t cause NEC, study suggests


 

Blood in bags and vials

Photo by Daniel Gay

Red blood cell (RBC) transfusions do not increase the risk of a serious intestinal disorder in very low-birth-weight (VLBW) infants, according to a study published in JAMA.

Past research has suggested RBC transfusions increase the risk of necrotizing enterocolitis (NEC) among VLBW infants.

But other studies have shown no association between transfusions and NEC or suggested transfusions actually have a protective effect.

So researchers set out to determine whether RBC transfusions or severe anemia were associated with the rate of NEC among VLBW infants. The results suggested a significant association for severe anemia but not RBC transfusion.

To conduct this study, Ravi M. Patel, MD, of the Emory University School of Medicine in Atlanta, Georgia, and his colleagues assessed 598 VLBW infants from 3 neonatal intensive care units in Atlanta.

The team followed the infants for 90 days or until they were discharged from the hospital, transferred to a non-study-affiliated hospital, or died (whichever came first).

Forty-four (7.4%) infants developed NEC, and 32 (5.4%) died (of any cause). Roughly half of the infants (n=319, 53%) received RBC transfusions (n=1430).

The unadjusted cumulative incidence of NEC at week 8 was 9.9% in infants who received transfusions and 4.6% in those who did not.

However, in multivariable analysis, exposure to RBC transfusion in a given week was not significantly related to the rate of NEC. The hazard ratio was 0.44 (P=0.09).

On the other hand, the rate of NEC was significantly higher among infants with severe anemia in a given week than in those without severe anemia. The hazard ratio was 5.99 (P=0.001).

The researchers said these results suggest preventing severe anemia may be more clinically important than minimizing the use of RBC transfusion as a strategy to decrease the risk of NEC in VLBW infants.

However, such a strategy might impact other important neonatal outcomes, so further study is needed.

Recommended Reading

Medicare to cover HSCT in approved clinical trials for myeloma, myelofibrosis, sickle cell disease
MDedge Hematology and Oncology
Do we give too much iron?
MDedge Hematology and Oncology
Human gene editing consensus study underway
MDedge Hematology and Oncology
EC approves drug for iron-deficiency anemia in IBD
MDedge Hematology and Oncology
Gene therapy could treat aplastic anemia
MDedge Hematology and Oncology
Histone levels may predict thrombocytopenia
MDedge Hematology and Oncology
Generic imatinib launched with savings program
MDedge Hematology and Oncology
EHA creates ‘roadmap’ for hematology research
MDedge Hematology and Oncology
Drug granted orphan designation for hemolytic anemia
MDedge Hematology and Oncology
Drug could aid standard care for aTTP
MDedge Hematology and Oncology